GRDN vs MCK vs MDT Stock Comparison

Guardian Pharmacy Services, Mckesson and Medtronic Prices as of Nov 13, 2026 Peers: Industry group
MCK Mckesson Corp
$1,102.82 +12.7% 1M +30.3% 1Y
Market cap
$128.85B
P/E
27.4x
Revenue (TTM)
$418.79B
Div. yield
0.00%
Drug Distribution Healthcare
3 wins
MDT Medtronic plc
$102.86 +9.2% 1M +7.0% 1Y
Market cap
$132.33B
P/E
25.3x
Revenue (TTM)
$37.54B
Div. yield
0.03%
Medical Devices Healthcare
7 wins

Head to Head

12 decided of 12

Medtronic leads on 7 of the 12 questions below (Medtronic 7, Mckesson 3, Guardian Pharmacy Services 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGRDNMCKMDTLeader
Larger companyMarket capitalisation $3.13B $128.85B $132.33B MDT
Cheaper on earningsLower P/E, profitable companies only 41.8x 27.4x 25.3x MDT
Cheaper on forward earningsLower price / next fiscal year consensus EPS 37.5x 22.8x 18.5x MDT
Faster revenue growthRevenue growth, trailing twelve months +4.9% +8.2% +12.8% MDT
More profitableNet margin, trailing twelve months 5.1% 1.1% 23.6% MDT
Better return on capitalReturn on invested capital — 98.7% 11.7% MCK
Less leveragedLower net debt / EBITDA — 0.4x 1.2x MCK
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.03% MDT
Better 1-year returnPrice return, last 12 months +62.6% +30.3% +7.0% GRDN
Better 5-year returnAnnualised price return, 5 years — +37.5%/yr -2.9%/yr MCK
Less volatileAnnualised volatility, 1 year 42.4% 31.4% 25.6% MDT
Higher overall scoreMean of the five percentile scores vs peers 71/100 58/100 63/100 GRDN

Percentile Scorecard

GRDNMCKMDT

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGRDNMCKMDT
Valuation 23 #21 of 27 65 #10 of 27 87 #32 of 243
Growth 76 #7 of 26 56 #12 of 26 35 #149 of 228
Profitability 96 #2 of 26 56 #12 of 26 98 #6 of 222
Financial Health 88 #4 of 26 56 #12 of 26 50 #124 of 248
Shareholder Returns – 59 #8 of 18 43 #90 of 158
Overall 71 58 63
  • GRDN ranked among 27 companies in Healthcare Payers and Distributors
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • MDT ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGRDNMCKMDTSPY
1 month +21.9%+12.7%+9.2% -2.0%
3 months +28.7%+26.9%+12.7% -2.8%
6 months +35.1%+45.0%+35.1% +2.0%
Year to date +64.4%+34.4%+7.1% +10.6%
1 year +62.6%+30.3%+7.0% +12.2%
3 years —+143.0%+41.7% +68.1%
3 years, per year —+34.5%+12.3% +18.9%
5 years —+390.5%-13.8% +61.4%
5 years, per year —+37.5%-2.9% +10.1%
10 years —+671.0%+25.3% +248.5%
10 years, per year —+22.7%+2.3% +13.3%

Risk

MeasureGRDNMCKMDTSPY
Volatility, 1Y 42.4%31.4%25.6% 13.6%
Downside volatility, 1Y 39.1%27.2%22.3% 13.9%
Beta vs S&P 500, 1Y 0.71-0.180.14 1.00
Return / volatility, 1Y 1.480.970.27 0.90
Max drawdown, 5Y -27.2%-27.2%-41.2% -25.4%
From 52-week high -1.1%0.0%-2.4% -3.2%
52-week high $50.01$1,102.82$105.35 $779.14
52-week low $27.03$725.17$73.75 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGRDNMCKMDT
P/E now vs peer median 41.9xmedian 25.2x 27.3xmedian 25.2x 15.0xmedian 26.5x
P/S now vs peer median 2.2xmedian 0.4x 0.3xmedian 0.4x 3.5xmedian 2.7x
EV/EBITDA now vs peer median 25.6xmedian 14.5x 17.4xmedian 14.5x 9.2xmedian 18.4x
P/FCF now vs peer median 40.0xmedian 16.5x 17.9xmedian 16.5x 10.3xmedian 25.4x
P/B now vs peer median 11.2xmedian 2.7x -32.2xmedian 2.7x 2.6xmedian 2.5x
PEG now vs peer median —median 1.72 1.72median 1.72 1.85median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGRDNMCKMDT
Revenue $1.46B $418.79B $37.54B
Gross profit $327.08M $15.37B $24.41B
Operating income $94.14M $6.69B $6.79B
Net income $74.77M $5.43B $5.27B
Free cash flow $78.35M $7.11B $6.13B
R&D – – $2.92B
EPS (diluted) $1.17 $40.27 $4.07
Cash & equivalents $119.66M $6.53B $1.69B
Total debt – $9.21B $28.15B
Shares (diluted) 63.92M 116.70M 1.29B
Enterprise value $2.79B $110.22B $97.58B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGRDNMCKMDT
P/E 41.9x 27.3x 15.0x
P/FCF 40.0x 17.9x 10.3x
P/Operating cash flow 27.5x 17.0x 10.7x
P/S 2.2x 0.3x 3.5x
P/B 11.2x -32.2x 2.6x
P/Tangible book 12.1x -16.1x 3.2x
EV/EBITDA 25.6x 17.4x 9.2x
EV/EBIT 32.0x 19.4x 13.4x
EV/Revenue 2.1x 0.3x 4.1x
EV/FCF 38.5x 18.3x 11.9x
EV/Operating cash flow 26.4x 17.3x 12.2x
PEG (3Y EPS CAGR) – 1.72 1.85

Growth

14 metrics
MetricGRDNMCKMDT
Revenue growth (1Y) 4.9% 8.2% 12.8%
Revenue CAGR (3Y) – 12.9% 6.7%
Gross profit growth (1Y) 19.2% 11.8% 13.1%
Gross profit CAGR (3Y) – 7.6% 6.0%
Operating income growth (1Y) 60.4% 27.3% 19.2%
Operating income CAGR (3Y) – 16.1% 5.7%
Net income growth (1Y) 85.8% 28.5% -17.8%
Net income CAGR (3Y) – 14.2% -4.4%
EPS growth (1Y) 84.4% 24.2% 24.7%
EPS CAGR (3Y) – 15.9% 8.1%
Operating cash flow growth (1Y) 29.6% 9.3% -22.3%
Operating cash flow CAGR (3Y) – 15.2% -6.7%
Free cash flow growth (1Y) 18.9% 11.8% 27.6%
Free cash flow CAGR (3Y) – 16.3% 6.7%

Profitability

14 metrics
MetricGRDNMCKMDT
Gross margin 22.4% 3.7% 65.3%
EBITDA margin 8.1% 1.8% 44.0%
Operating margin 6.5% 1.6% 30.4%
Pretax margin 7.2% 1.6% 29.2%
Net margin 5.1% 1.1% 23.6%
FCF margin 5.4% 1.7% 34.3%
Operating cash flow margin 7.8% 1.8% 33.2%
Return on equity 28.3% – 17.5%
Return on assets 16.3% 6.0% 9.5%
Return on invested capital – 98.7% 11.7%
Return on capital employed 32.6% 42.0% 13.9%
Asset turnover 3.1x 4.6x 0.4x
Cash conversion (OCF / net income) 1.5x 1.4x 1.4x
Stock comp / revenue 0.6% – 2.2%

Financial Health

11 metrics
MetricGRDNMCKMDT
Debt / assets – 10.0% 30.2%
Debt / equity – -2.3x 0.6x
Net debt / EBITDA – 0.4x 1.2x
Debt / FCF – 1.3x 2.2x
Liabilities / assets 43.1% 104.3% 45.5%
Equity / assets 56.9% -4.3% 54.5%
Interest coverage 145.3x 21.9x 8.9x
Current ratio 1.6x 0.9x 2.1x
Quick ratio 1.3x 0.5x 1.3x
Cash ratio 0.7x 0.1x 0.7x
Altman Z-score 13.09 5.83 3.32

Shareholder Returns

7 metrics
MetricGRDNMCKMDT
Dividend yield – 0.3% 2.8%
Net buyback yield – 5.2% -2.6%
Shareholder yield – 5.6% 0.1%
Payout ratio (earnings) – 7.4% 41.4%
Payout ratio (FCF) – 5.6% 28.7%
Dividend growth (1Y) – 10.5% 0.7%
Dividend CAGR (3Y) – 9.8% 0.7%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGRDNMCKMDT
Forward P/E 37.5xFY2026 22.8xFY2026 18.5xFY2026
EPS, next fiscal year $1.32FY2026 $48.34FY2026 $5.57FY2026
EPS growth, next FY +23.4%FY2026 +23.6%FY2026 +0.7%FY2026
EPS growth, the year after +18.9% +11.9% +7.4%
Revenue, next fiscal year $1.42BFY2026 $447.65BFY2026 $39.92BFY2026
Revenue growth, next FY -2.2%FY2026 +11.0%FY2026 +9.8%FY2026
Revenue growth, the year after +2.7% +1.5% -4.7%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGRDNMCKMDT
Held by institutions 58.6% 89.1% 85.1%
Institutions holding 189 2,014 2,128
Change in shares held, QoQ +3.8% -0.7% -0.2%
Institutions buying 109 883 1,015
Institutions selling 54 793 915
Buyers to sellers 2.02 1.11 1.11

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GRDNMCKMDT
GRDN 1.00 0.18 0.13
MCK 0.18 1.00 0.36
MDT 0.13 0.36 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GRDN, MCK and MDT?

Medtronic (MDT) is the largest by market capitalisation: Guardian Pharmacy Services (GRDN) $3.13B, Mckesson (MCK) $128.85B, Medtronic (MDT) $132.33B.

Which stock is cheaper, GRDN, MCK and MDT?

Medtronic (MDT) trades on the lowest price-to-earnings ratio (Guardian Pharmacy Services (GRDN) 41.8x, Mckesson (MCK) 27.4x, Medtronic (MDT) 25.3x). On next year's consensus earnings, Medtronic (MDT) is cheapest (Guardian Pharmacy Services (GRDN) 37.5x, Mckesson (MCK) 22.8x, Medtronic (MDT) 18.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Medtronic (MDT) grew revenue fastest over the trailing twelve months: Guardian Pharmacy Services (GRDN) +4.9%, Mckesson (MCK) +8.2%, Medtronic (MDT) +12.8%.

Which company is more profitable?

Medtronic (MDT) has the highest net margin (Guardian Pharmacy Services (GRDN) 5.1%, Mckesson (MCK) 1.1%, Medtronic (MDT) 23.6%). On return on invested capital, Mckesson (MCK) leads (Mckesson (MCK) 98.7%, Medtronic (MDT) 11.7%).

Which stock has performed better?

Over the past year Guardian Pharmacy Services (GRDN) returned the most: Guardian Pharmacy Services (GRDN) +62.6%, Mckesson (MCK) +30.3%, Medtronic (MDT) +7.0%. Over five years, Mckesson (MCK) compounded fastest (Mckesson (MCK) +37.5%/yr, Medtronic (MDT) -2.9%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Medtronic (MDT) has the highest dividend yield: Guardian Pharmacy Services (GRDN) 0.00%, Mckesson (MCK) 0.00%, Medtronic (MDT) 0.03%. Guardian Pharmacy Services (GRDN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Medtronic (MDT) has been the steadiest (Guardian Pharmacy Services (GRDN) 42.4%, Mckesson (MCK) 31.4%, Medtronic (MDT) 25.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GRDN, MCK and MDT?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Medtronic (MDT) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.